Our ambition to translate innovations in peptide and protein science for human benefit, such as through ecofriendly bio-pesticides for sustainable food production and potent and cost effective new therapeutics, can only be achieved through the strength and reach of our industry partners. We are proud to collaborate with the following partners who collectively span Big Pharma, Ag Biotech, instrumentation, sequencing, biotech, manufacturing and education sectors. Details of each of these partners and their relevant expertise for the Centre is outlined below.
For more information on collaboration and partnership opportunities with CIPPS, please contact our Chief Operating Officer Dr Richard Kim at email@example.com
AGRICULTURE AND FOOD
The Centre partners with CSIRO to foster translational outcomes across biotechnology, food and manufacturing sectors. The Food Science Division provides expertise in peptidomics/proteomics, bioinformatics and bioactivity of peptides for digestibility and intestinal uptake. The Manufacturing Division provides expertise in large scale manufacture of peptide and protein products for field trials and animal studies, as well as large-scale continuous flow microfluidics for semi-automated synthetic peptide production.
AstraZeneca is a multinational pharmaceutical and biopharmaceutical company with established collaboration with CIPPS researchers. The partnership with AstraZeneca will foster the translation of peptide-based drug design towards high value pharmaceutical targets, and the potential for a vast expansion of chemical space in the field of peptide-based drug design.
Novo Nordisk is a world leader in peptide and protein therapeutics development supplying nearly half the world’s insulin. Their partnership will deepen linkages with Deputy Director Payne’s group in the area of chemical synthesis of post-translationally modified proteins. The partnership with CIPPS will enable Novo to develop new collaborations with other Centre CIs in peptide design through machine learning and artificial intelligence.
Innovate Ag is an Australian bio-pesticide company that has partnered with Director Craik and CIPPS researchers over more than a decade. This collaboration has developed Sero-X as a sustainable, environmentally responsible pesticide to support global food security by protecting the world’s pollinators.
Hexima is an unlisted Australian biotech company that has discovered and patented a large range of antifungal and insecticidal proteins and peptides for crop protection and has collaborated with leading Ag Biotech companies including Dow, Monsanto, DuPont and Corteva Agriscience.
SCIEX provides a range of innovative instruments, software and reagents to examine the proteome more completely to discover, identify, quantitate and interpret key proteins, lipids and metabolites in complex biological systems. They will extend this collaboration with CI Colgrave and CSIRO across the relevant CIPPS research programs.
Vapourtec develop and manufacture the revolutionary R-Series flow chemistry system in use by CSIRO collaborators and Deputy Director Payne's group to support the CIPPS goal of building an automated protein synthesiser.
Bioplatforms Australia provides access to world-class capabilities and infrastructure in genomics, proteomics, metabolomics and bioinformatics technologies. Bioplatforms is enabled by the Australian Government's National Collaborative Research Infrastructure Strategy.
Beta Therapeutics provides assay capabilities for inflammation, enzyme inhibition and eye health as well as proprietary drug compounds as comparative compound controls, and will extend their collaboration with CIPPS researchers, in particular CIs Jackson and Malins, in the area of molecular design, structure determination and functional assays.
Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle for the pharmaceutical and biotech sectors. Almac engages with CIPPS researchers in providing expertise in peptide manufacture and industrial training and mentoring.
The Centre's outreach and engagement portfolio partners with Questacon to develop engaging new content that promotes deeper participation and engagement with science. Questacon hosts a world-class science centre, digital studio and makerspace facilities in the nation's capital, Canberra, as well as capabilities for travelling exhibitions and teacher professional learning. This partnership will enable our Centre to bring the 'CIPPS story' to new audiences, including those in regional and remote communities.